122 related articles for article (PubMed ID: 38143437)
1. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan.
Ito T; Kaku-Ito Y; Ohno F; Nakahara T
Front Med (Lausanne); 2023; 10():1293397. PubMed ID: 38143437
[TBL] [Abstract][Full Text] [Related]
2. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Cantini L; Paoloni F; Pecci F; Spagnolo F; Genova C; Tanda ET; Aerts S; Rebuzzi SE; Fornarini G; Zoratto F; Fancelli S; Lupi A; Della Corte CM; Parisi A; Bennati C; Ortega C; Atzori F; Piovano PL; Orciuolo C; De Tursi M; Ghidini M; Botticelli A; Scagnoli S; Belluomini L; Leporati R; Veccia A; Di Giacomo AM; Festino L; Cortinovis D; Acquati M; Filetti M; Giusti R; Tucci M; Sergi MC; Garutti M; Puglisi F; Manglaviti S; Citarella F; Santoni M; Rijavec E; Lo Russo G; Santini D; Addeo A; Antonuzzo L; Indini A; Rocchi MBL; Cortellini A; Grossi F; Ascierto PA; Aerts JGJV; Berardi R
J Natl Cancer Inst; 2023 Jul; 115(7):796-804. PubMed ID: 37042716
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study.
Colard-Thomas J; Manceron C; Duflos C; Herman F; Simon M; Maria ATJ; Faillie JL; Viala M; Palassin P
ESMO Open; 2023 Dec; 8(6):102070. PubMed ID: 37988951
[TBL] [Abstract][Full Text] [Related]
4. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
5. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.
Truong J; Yeung SST; Kletas V; de Lemos M; Schaff K; Nakashima L
J Oncol Pharm Pract; 2023 Sep; ():10781552231199048. PubMed ID: 37654194
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
8. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
10. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
Klee G; Kurzhals J; Hagelstein V; Zillikens D; Recke A; Langan EA; Terheyden P
Melanoma Res; 2021 Oct; 31(5):464-471. PubMed ID: 34284462
[TBL] [Abstract][Full Text] [Related]
11. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
Almutairi AR; McBride A; Slack M; Erstad BL; Abraham I
Front Oncol; 2020; 10():91. PubMed ID: 32117745
[No Abstract] [Full Text] [Related]
12. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.
Morimoto K; Yamada T; Morimoto Y; Ishikawa T; Asai J; Fujihara A; Arai A; Katoh N; Ukimura O; Hirano S; Itoh Y; Takayama K
Int Immunopharmacol; 2022 Jul; 108():108775. PubMed ID: 35436741
[TBL] [Abstract][Full Text] [Related]
13. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
[TBL] [Abstract][Full Text] [Related]
14. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Nivolumab and Ipilimumab Combined Therapy as a First-Line Therapy for Patients with Advanced Melanoma and the Urgent Need for an Effective Second-Line Therapy for Patients with Wild-Type BRAF in Japan: A Single Center Retrospective Study.
Muto I; Koga H; Doi R; Katayama E; Nakama K; Nakama T
Kurume Med J; 2023 Nov; 69(1.2):75-80. PubMed ID: 37793888
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
17. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB
Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
19. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
McQuade JL; Hammers H; Furberg H; Engert A; André T; Blumenschein G; Tannir N; Baron A; Larkin J; El-Khoueiry A; Carbone DP; Thomas JM; Hennicken D; Coffey M; Motzer RJ
JAMA Oncol; 2023 Jan; 9(1):102-111. PubMed ID: 36480191
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
Gupta M; Stukalin I; Meyers D; Goutam S; Heng DYC; Cheng T; Monzon J; Navani V
JAMA Netw Open; 2023 Jun; 6(6):e2319607. PubMed ID: 37351883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
